Dainippon Sumitomo Pharma Co Ltd (DNPUF/DNPUF.PK) Wrap Up:

Dainippon Sumitomo Pharma Co., Ltd. engages in the manufacture, import, and sale of pharmaceuticals, veterinary products, food additives, industrial chemicals, and other chemical products. It operates in two segments, Pharmaceuticals and Other products. The Pharmaceuticals segment offers various cardiovascular system drugs, antibacterial and antibiotic agents, central nervous system and anti allergic drugs, and gastrointestinal drugs. The company's pharmaceuticals products include AMLODIN, a therapeutic agent for the treatment of hypertension and angina pectoris; GASMOTIN, a gastroprokinetic agent; PRORENAL, a vasodilator; and MEROPEN, a carbapenem antibiotic. It also offers EBASTEL, an anti allergic agent; SUMIFERON, a natural alpha interferon; GROWJECT, a growth hormone; DOPS, Noradrenaline-activating neural function ameliorant; EXCEGRAN, an antiepileptic agent; QVAR for bronchial asthma; GLIMICRON and MELBIN, oral hypoglycemics; LONASEN and LULLAN, an antipsychotic agent; and AmBisome, a therapeutic agent for systemic fungal infection. In addition, Dainippon Sumitomo Pharma provides ALMARL, a therapeutic agent for hypertension, angina pectoris, and arrhythmia; TAGAMET, a H2-receptor antagonist; SEDIEL, serotonin-agonist anti anxiety drug; and AVAPRO, a therapeutic agent for hypertension. The Other products segment provides animal health products, feeds and feed additives, food additives, industrial chemicals, diagnostics, and research reagents and materials. Dainippon Sumitomo Pharma Co. has a collaboration agreement with Silence Therapeutics plc to demonstrate the functional delivery of Silence's proprietary short interfering RNA molecules to specific targets. The company was founded in 1897 and is headquartered in Osaka, Japan. Dainippon Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Co. Ltd.